V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330004339 | 330002122 | 1.48 | 72.3 | Not known (9) | null | 2016-03-25 | METHOTREXATE | null | null | 330017357 | MIDOSTAURIN |
| 330004340 | 330002122 | null | 56 | null | 2016-04-03 | 2016-04-03 | FLUOROURACIL + MITOMYCIN + RT | N | N | 330017357 | METHOTREXATE HIGH DOSE |
| 330004341 | 330002123 | 1.74 | 80 | null | 2014-03-25 | 2014-03-26 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 02 | N | 330017367 | CLADRIBINE |
| 330004342 | 330002123 | 1.8 | 56.05 | Curative (C) | 2014-11-13 | 2014-11-25 | Bendamustine +/- Prednisolone | null | null | 330017367 | BEP |
| 330004343 | 330002124 | 0 | 37.3 | Curative (C) | 2017-06-05 | 2017-06-22 | CLADRIBINE | 02 | Y | 330017387 | CARBOPLATIN + RT |
| 330004344 | 330002125 | 1.52 | 104 | Curative (C) | null | 2014-02-20 | EOX | null | null | 330017399 | CARBOPLATIN + RT |
| 330004345 | 330002125 | 1.63 | 76 | Curative (C) | 2014-02-27 | 2014-03-31 | MITOTANE | N | N | 330017399 | CHLORAMBUCIL |
| 330004346 | 330002126 | null | 102.1 | Palliative (P) | 2015-05-15 | 2015-05-15 | Trabectedin | N | null | 330017403 | VINBLASTINE |
| 330004347 | 330002126 | 1.61 | 11 | Curative (C) | 2013-06-29 | 2013-07-08 | IVA | N | N | 330017403 | CASPS TRIAL |
| 330004348 | 330002126 | 1.83 | 79 | Adjuvant (A) | 2014-01-10 | 2014-01-27 | Bortezomib + Cyclophos + Dex | 02 | N | 330017403 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 330004349 | 330002127 | 0 | 92.7 | Disease modification (D) | null | 2014-04-19 | Bortezomib (weekly) | null | null | 330017415 | VINBLASTINE |
| 330004350 | 330002127 | null | 53.9 | null | 2015-04-30 | 2015-08-04 | AML17 TRIAL | N | N | 330017415 | METHOTREXATE HIGH DOSE |
| 330004351 | 330002127 | 1.73 | 66 | null | 2016-08-30 | 2016-09-03 | Etoposide + Ifosfamide (5 days) | 2 | N | 330017415 | BEVACIZUMAB |
| 330004352 | 330002127 | 1.62 | 60.2 | Palliative (P) | 2015-10-28 | 2015-10-31 | VIDE | N | N | 330017415 | LIPOSOMAL DAUNORUBICIN |
| 330004353 | 330002127 | null | 66 | Palliative (P) | 2016-09-05 | 2016-09-06 | Doxorubicin + Ifosfamide | N | N | 330017415 | MIDOSTAURIN |
| 330004354 | 330002127 | 1.6 | 86.7 | Curative (C) | 2016-10-28 | 2016-11-04 | Cisplatin+Doxorubicin+Etoposide 28d | N | N | 330017415 | PEMBROLIZUMAB |
| 330004355 | 330002127 | 1.62 | null | Neo-adjuvant (N) | 2015-06-28 | 2015-07-17 | CHLORAMBUCIL + RITUXIMAB | N | Y | 330017415 | OCTREOTIDE |
| 330004356 | 330002128 | 1.77 | 50 | Curative (C) | 2015-04-26 | 2015-04-28 | LIPOSOMAL DAUNORUBICIN | 02 | N | 330017458 | PACLITAXEL |
| 330004357 | 330002128 | 1.7 | 12.8 | Curative (C) | 2013-01-20 | 2013-02-11 | VAC | N | N | 330017458 | CARBOPLATIN + VINCRISTINE |
| 330004358 | 330002129 | 1.7 | 43.7 | Palliative (P) | 2014-02-02 | 2014-02-10 | FCR | N | N | 330017463 | AML18 TRIAL |
| 330004359 | 330002129 | 1.77 | null | Curative (C) | 2015-06-10 | 2015-07-02 | Bortezomib + Cyclophos + Dex | 02 | N | 330017463 | AML16 TRIAL |
| 330004360 | 330002129 | 0 | 77 | Palliative (P) | 2014-10-25 | 2014-11-04 | BEP 5 Day | 02 | N | 330017463 | ECARBOX |
| 330004361 | 330011398 | 1.7 | 60 | Curative (C) | 2014-05-10 | 2014-05-10 | Capecitabine + Cisplatin | 2 | N | 330017470 | DHAP - R |
| 330004362 | 330002130 | 1.77 | 115.2 | Disease modification (D) | 2015-09-06 | 2015-09-06 | PEMBROLIZUMAB | N | N | 330017481 | CYTARABINE |
| 330004363 | 330002130 | 1.66 | 72.3 | Curative (C) | 2017-04-12 | 2017-04-16 | Gemcitabine day 1&8 | 01 | null | 330017481 | BEP |
| 330004364 | 330002131 | 1.65 | 12 | Curative (C) | 2017-02-13 | 2017-03-09 | Mitotane 2g | N | N | 330017489 | DACARBAZINE |
| 330004365 | 330002131 | 1.71 | null | null | null | 2017-11-12 | Cetuximab +Cisplatin + FU (Cycle 1) | null | null | 330017489 | CLADRIBINE |
| 330004366 | 330002131 | 1.68 | null | null | 2015-10-20 | 2015-10-24 | AC | N | N | 330017489 | FLAG + IDARUBICIN |
| 330004367 | 330002131 | null | 103 | Curative (C) | 2017-12-06 | 2017-12-06 | RUXOLITINIB | Y | Y | 330017489 | VINBLASTINE |
| 330004368 | 330002132 | 1.62 | 77 | Palliative (P) | 2016-01-04 | 2016-02-09 | Mercaptopurine | N | Y | 330017507 | VIDE |
| 330004369 | 330002132 | 1.75 | 77.7 | Neo-adjuvant (N) | 2013-06-19 | 2013-06-27 | AC | Y | N | 330017507 | MIFAMURTIDE |
| 330004370 | 330009888 | null | 116.25 | Curative (C) | 2017-02-16 | 2017-05-28 | AML18 PILOT TRIAL | N | N | 330017512 | SUNITINIB |
| 330004371 | 330002133 | 1.78 | 81.1 | Curative (C) | null | 2016-05-10 | Cyclophosphamide Fludarabine (Oral) | 02 | N | 330017513 | UKALL2014 |
| 330004372 | 330002133 | 1.67 | 5.2 | Palliative (P) | 2014-01-08 | 2014-01-25 | ALL Int Guide A/B/C Maint Ph V | N | N | 330017513 | CYCLO + RITUXIMAB + VINCRISTINE |
| 330004373 | 330002134 | 1.83 | null | Curative (C) | 2015-10-06 | 2015-10-06 | BEP 3 day | 02 | N | 330017535 | PACLITAXEL |
| 330004374 | 330002134 | 1.6 | 54.4 | Adjuvant (A) | 2015-02-03 | 2015-02-13 | VIDE | 02 | N | 330017535 | GEMCITABINE |
| 330004375 | 330009889 | 1.75 | 69.1 | Neo-adjuvant (N) | 2015-10-10 | 2015-10-30 | Capecitabine + Cisplatin | 2 | N | 330017552 | IPILIMUMAB |
| 330004376 | 330002135 | 1.83 | 95.3 | null | 2016-08-21 | 2016-08-22 | VINCRISTINE | null | N | 330017557 | CARBOPLATIN + VINCRISTINE |
| 330004377 | 330002135 | null | null | Disease modification (D) | null | 2016-09-30 | FCR | null | null | 330017557 | AML18 TRIAL |
| 330004378 | 330002135 | 1.75 | null | Not known (9) | 2014-03-21 | 2014-03-30 | CARBOPLATIN + EPIRUBICIN + PACLITAXEL | 2 | Y | 330017557 | VINCRISTINE |
| 330004379 | 330002135 | 1.6 | 11.9 | Curative (C) | 2016-01-12 | 2016-01-12 | CISPLATIN + CYCLO + DOXORUBICIN | 02 | N | 330017557 | VINCRISTINE |
| 330004380 | 330002135 | null | null | Adjuvant (A) | null | 2013-05-15 | CARBOPLATIN + RT | null | null | 330017557 | CYTARABINE INTRATHECAL |
| 330004381 | 330002136 | 1.62 | 38 | null | 2016-10-08 | 2016-10-09 | VDC | N | N | 330017577 | CISPLATIN + DOXORUBICIN + ETOPOSIDE |
| 330004382 | 330002137 | null | null | Palliative (P) | 2015-02-15 | 2015-03-14 | Hydroxycarbamide | N | N | 330017579 | PACLITAXEL |
| 330004383 | 330002137 | 0 | 68.2 | Disease modification (D) | 2013-03-09 | 2013-03-09 | ALL UKALL60+ TRIAL | 2 | N | 330017579 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 330004384 | 330002138 | 1.67 | 64.8 | Palliative (P) | 2013-07-14 | 2013-07-17 | ALL UKALL2011 Cap Int Maint C PAsp | 2 | N | 330017605 | CHLORAMBUCIL + RITUXIMAB |
| 330004385 | 330002138 | 1.8 | 0 | Palliative (P) | 2014-01-27 | 2014-02-28 | MITOMYCIN | N | N | 330017605 | IRINOTECAN + TEMOZOLOMIDE |
| 330004386 | 330002138 | 1.76 | 0 | Palliative (P) | 2014-04-20 | 2014-04-28 | ECarboX | N | N | 330017605 | CHOP |
| 330004387 | 330002139 | 1.7 | 116.25 | Curative (C) | 2014-07-14 | 2014-07-16 | Chlorambucil | N | null | 330017629 | AZACITIDINE |
| 330004388 | 330002140 | 1.59 | 70.7 | Palliative (P) | 2015-01-19 | 2015-01-22 | Mifamurtide weeks 13-36 | 02 | N | 330017647 | IPILIMUMAB + NIVOLUMAB |